ALIROCUMAB
Information current as at: 1 May 2025
The pharmaceutical company has not advised whether they intend to proceed or not within 60 days of receiving the ratified PBAC minutes. The process for listing is considered inactive.
Submission Details
- Brand name:
-
- Praluent®
- Pharmaceutical company:
- Sanofi-Aventis Australia Pty Ltd
- Condition/indication:
(therapeutic use) -
- Familial heterozygous hypercholesterolaemia and non-familial hypercholesterolaemia.
- PBAC Submission type:
- New listing (Category 4)
- Comment:
- --
- Public Summary Document:
- PBAC Public Summary Documents – March 2023
- Related medicines:
Progress Details
-
Submission received for: - March 2023 PBAC meeting
-
Opportunity for consumer comment: - Open 23/11/2022 and close 25/01/2023 (see PBS Website)
-
PBAC meeting: - Held on 08/03/2023
-
PBAC outcome published: - Recommended (see PBAC Outcomes)
-
Notice of intent submitted:
- Awaiting lodgement from pharmaceutical company
-
5Lodgement of required documentation:
- Has not yet commenced
-
6Agreement to listing arrangements:
- Has not yet commenced
-
7Government processes:
- Has not yet commenced
-
8Medicine listed on the PBS:
- Has not yet occurred
Case ID: a629
Page last updated: 31 October 2024